Compare ATYR & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | DRDB |
|---|---|---|
| Founded | 2005 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.6K | 326.9M |
| IPO Year | 2015 | 2024 |
| Metric | ATYR | DRDB |
|---|---|---|
| Price | $6.59 | $10.77 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $114.29 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 81.7K |
| Earning Date | 11-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $597.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $10.42 |
| 52 Week High | $6.42 | $10.77 |
| Indicator | ATYR | DRDB |
|---|---|---|
| Relative Strength Index (RSI) | 93.06 | 58.79 |
| Support Level | $0.54 | $10.50 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.31 | 0.02 |
| MACD | 0.77 | -0.00 |
| Stochastic Oscillator | 97.54 | 75.00 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Roman DBDR Acquisition Corp II is a blank check company.